About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Wednesday, December 9th, 2015

The QualityStocks
Daily Stock List


Elite Pharmaceuticals, Inc. (ELTP)

Pennybuster, PennyStocks24, TopPennyStockMovers, SmallCapVoice, and Top Stock Picks reported earlier on Elite Pharmaceuticals, Inc. (ELTP), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products.  In addition, it provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). The Company has also partnered with Epic Pharma (a private pharmaceutical company in Laurelton, New York) for the manufacturing and distribution of approved products pending manufacturing site, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong headquartered company to develop a branded product for the United States market and its territories. Elite Pharmaceuticals’ shares trade on the OTC Bulletin Board.

Elite Pharmaceuticals operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, New Jersey, its headquarters. The Company owns generic and Over-the-Counter (OTC) products licensed to TAGI Pharma, Epic Pharma, and Valeant Pharmaceuticals International, with eight commercial products now selling, additional approved products pending manufacturing site transfer, and a product under review pending approval by the Food and Drug Administration (FDA).

Elite’s lead pipeline products include abuse resistant opioids using its patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain. These address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse.

Last month, Elite Pharmaceuticals announced results for the quarter ended September 30, 2015, Q2 of its 2016 Fiscal Year. Consolidated revenues for Q2 of Fiscal 2016 were $2.7 million. This represents a 115 percent increase on a year-on-year basis.  The increase in revenues is because of the continued growth of the Company’s niche generic product lines. During the quarter, Elite invested an additional $4.2 million in the development of ELI-200, which is the first product in its line of abuse-deterrent opioids.

This past October, Elite Pharmaceuticals announced positive top-line results from the Phase 3 pivotal trial of its lead abuse-deterrent opioid, ELI-200, for the treatment of moderate to severe pain. Elite is on schedule to file a New Drug Application with the FDA later this year.

Elite Pharmaceuticals, Inc. (ELTP), closed Wednesday's trading session at $0.4122, up 5.15%, on 3,541,410 volume with 502 trades. The average volume for the last 60 days is 2,012,166 and the stock's 52-week low/high is $0.195/$0.443.

CÜR Media, Inc. (CURM)

RedChip reported earlier on CÜR Media, Inc. (CURM), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

CÜR Media, Inc. is creating a next generation social music experience. This is through the launch of CÜR Music. This is a social streaming music application and website. It enables its users to go beyond the limitations of traditional music streaming services. CÜR Media is based in South Glastonbury, Connecticut and the Company’s shares trade on the OTC Bulletin Board.

CÜR Media is led by Mr. Tom Brophy. He is a successful digital media entrepreneur. The Company is also led by entertainment and music industry veterans Mr. John A. Lack (creator of MTV, Nickelodeon, ESPN2, and The Movie Channel) and Mr. Bob Jamieson (former Chairman/Chief Executive Officer of RCA Records).

CÜR Media unlocks the true expressive nature of an individual's connection with their music through promoting personalization, sharing, and also creativity. CÜR Music began testing in early 2012 as Raditaz, a DMCA compliant Internet radio product. It has developed iPhone and Android applications that in beta had in excess of 150,000 monthly unique users.

CÜR Music will target consumers who are looking for a more complete music streaming service than current free, ad-supported music streaming products. The Company believes that the CÜR Music product will include a hybrid model that includes many features that free, ad-supported internet radio products provide, without interruptive advertising, with a limited on-demand offering. It will also include a social toolset that allows consumers to curate certain aspects of their playlists.

CÜR Media announced in May 2015 that it released the Beta testing version of CÜR Music for Android.  CÜR Music is its next generation social music streaming application expected to launch later in 2015 on mobile and web. With the Company’s release of its Beta version for Android, it now has all CÜR Music platforms in the final phase of testing for its planned launch this year.

This past October, CÜR Media announced a strategic partnership with DigitasLBi, a global marketing and technology agency.  With this agreement, DigitasLBi New York will provide strategic planning, media buying, marketing and creative support associated with the launch of CÜR Media’s next generation music streaming app, CÜR, scheduled for this year.

CÜR Media, Inc. (CURM), closed Wednesday's trading session at $0.62, up 3.40%, on 65,808 volume with 23 trades. The average volume for the last 60 days is 19,445 and the stock's 52-week low/high is $0.363/$1.44.

Praxsyn Corp. (PXYN)

Profit Status, Information Solutions Group, EmergingStockPlays, StockPickVIP, OtcShortReport, Pennystocktweeters.com, Impressive Penny Stocks, OTCMagic, Winston Small Cap, Penny Stock Circle, and Bull Trends reported earlier on Praxsyn Corp. (PXYN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Praxsyn Corp. concentrates on providing custom compounded non-narcotic, transdermal topical pain medications to industrial health physicians and clinics. Currently, the Company formulates transdermal creams in its compounding pharmacy, Mesa Pharmacy, Inc. It has developed a series of topical ointments for pain relief. Praxsyn is working on establishing its Point of Care/In-Office Dispensing Program, and its’ In-Office Toxicology Testing. NexGen Med Solutions, LLC is a wholly-owned subsidiary of Praxsyn. Praxsyn is based in Irvine, California.

The Company’s Point-Of-Care Services will provide the health care provider with pharmaceuticals and testing services, which are convenient and easy for physicians and staff. Its wholly-owned subsidiary, Mesa Pharmacy, provides doctors with an alternative to oral pain medications. Mesa Pharmacy centers on providing custom compounded non-narcotic, transdermal topical pain medications. These are marketed to the aforementioned industrial health physicians and medical clinics.

Mesa Pharmacy has developed a series of topical creams, in different strengths. The transdermal creams are tailored to patients suffering from long-term pain associated with work place related injuries. Praxsyn, via Mesa Pharmacy, provides a series of formulations that are compounded by using Food and Drug Administration (FDA) approved pain medication formulations to help patients suffering from pain associated with injuries. Through compounding, a patient can receive medication exactly formulated for his or her needs and medical history.

Praxsyn’s NexGen Med Solutions is a billing and collections company. NexGen formed to enable Praxsyn to manage its accounts receivables in a more cost-effective and efficient manner. The expectation is that this new subsidiary will provide an integrated alternative to prior billing and collections procedures. NexGen Med Solutions specializes in the billing and collections of worker's compensation claims.

Praxsyn has started to process Preferred Provider Organization (PPO) prescriptions. Mesa Pharmacy’s dedication is to providing medical practitioners with medications for patients by way of this move into the PPO network with its new and advanced products. Mesa has now expanded its advanced and non-addictive product line beyond topical creams to also include capsules, patches, and shampoos.

In July 2015, Praxsyn announced that it finalized a lease on a new building for the Company’s pharmacy lab and billing services. Expansion efforts are now taking place. The new building will permit Praxsyn’s Mesa Pharmacy to considerably increase the size of its pharmacy lab, providing capacity for new equipment, a more diverse list of offered medications, and to continue the growth of its pharmacy staff. Moreover, this expansion will provide additional space for NexGen Med Solutions.

Praxsyn Corp. (PXYN), closed Wednesday's trading session at $0.007, up 7.69%, on 8,322,355 volume with 59 trades. The average volume for the last 60 days is 1,966,101 and the stock's 52-week low/high is $0.005/$0.06.

First Titan Corp. (FTTN)

MarketWatch reported recently on First Titan Corp. (FTTN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 2010, First Titan Corp.’s commitment, via its wholly-owned subsidiary, First Titan Energy, LLC, is to the exploration and development of oil and natural gas resources around the world. It is employing unique technology to extract oil and gas resources in the United States, which were once considered too difficult or too expensive to recover. First Titan owns interests in wells in Alabama, Oklahoma, Texas, and Louisiana.

The Company’s intention is to invest in oil and gas properties, greenfield projects, and in the development of pioneering exploration and production technologies. It continually looks to partner with energy developers that are pursuing ground-breaking new methods of oil and gas extraction. This includes the development of new technologies, cleaner methods, in addition to unconventional resources. Recently, First Titan said that it believes it has found a lucrative new source of future revenues and is pursuing opportunities in a market some are abandoning. This market is oil field services.

First Titan announced in 2014 that it negotiated and signed an agreement with a Houston, Texas-based private oil and gas company to jointly acquire and develop oil and gas leases across nine Texas counties. Its joint development agreement with the private company covers Bell, Milam, Falls, Robertson, Limestone, Freestone, Leon, Madison and Brazos counties in Texas. First Titan’s private partner will take the lead in securing leases and operating any wells re-entered or drilled on the acquired acreage.

First Titan announced in 2014 a substantial increase in its net leased acreage and the start of pre-drill planning on its Mustang Project in East Central Texas. Its operator notified First Titan that 1,000 acres were leased in the Mustang Project region. This area covers nine counties of the State. First Titan acquired a 25 percent working interest (WI) in the Mustang Project in March of 2014. The region has proven productive from different oil and gas formations, namely the Austin Chalk, Buda, Georgetown and Bossier.

First Titan has a 1 percent WI in one well in Little Cedar Creek Field in Alabama; and a 1.8 percent WI in the South Lake Charles Prospect situated to the south of the city of Lake Charles, Louisiana. Additionally, it has a 30 percent WI in the Minns project in Waller County, Texas.

Last week, First Titan announced that it signed an oil, gas and minerals option with Mustang Loan Co. for one of Mustang’s properties close to Abilene, Texas. This move is part of First Titan’s ongoing strategic efforts to acquire leases at discounts from companies hit hard by the continuing oil price downturn. This field is on the westernmost edge of the Barnett Shale.

Today, First Titan announced that it is closely examining possibilities in the fast growing gas-to-liquids market. This is an emerging energy sector. This sector offers robust potential as a fuel source free of the present low-price problems now associated with crude oil.

First Titan Corp. (FTTN), closed Wednesday's trading session at $0.345, down 6.76%, on 68,434 volume with 39 trades. The average volume for the last 60 days is 25,318 and the stock's 52-week low/high is $0.004/$2.60.

CLS Holdings USA, Inc. (CLSH)

Money TV reported this week on CLS Holdings USA, Inc. (CLSH), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

CLS Holdings USA, Inc. is a development stage diversified cannabis company. CLS stands for "Cannabis Life Sciences," in recognition of its patent pending proprietary method of extracting various cannabinoids from the marijuana plant and converting them into a higher quality and quantity of products. CLS Holdings USA specializes in the extraction and conversion of cannabinoids. The Company is headquartered in Boulder, Colorado.

CLS’s corporate mission is to be the industry leader in the extraction, conversion and marketing of cannabinoid oils, wax, edibles and shatter through taking advantage of its proprietary extraction methods and conversion processes. Its business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation, as well as consulting services.

For the past two years, one of the founders of CLS Labs has been developing a proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates (oils, waxes, edibles and shatter). These concentrates may be ingested in several ways, including through vaporization via electronic cigarettes, and used for an assortment of pharmaceutical and other purposes.

CLS’s intention is to monetize this extraction method and generate revenues through the licensing of its proprietary methods and processes to others, as in the Colorado Arrangement, the processing of cannabis for others, and the purchase of cannabis and the processing and sale of cannabis-related products.

CLS Holdings USA has sponsored the inaugural white paper by MJIC Media, a marijuana media conglomerate. The white paper, "State by State Packaging Rules Regarding Cannabis: Summary without Cynicism," addresses specifics within cannabis packaging and labeling. This includes images, logos and resemblances; regulatory speed; expiration dates; and an alphabetical state-by-state review, with all the states that have legalized at least some possession or consumption of cannabis. The discussion of each state's rules and regulations is supplemented by a link to a more official and complete source of information.

Mr. Jeff Binder, CLS Holdings USA’s Chief Executive Officer, said, "It is important that we, as an industry, move to standardize testing and labeling across state lines. MJIC Media is at the forefront of disseminating information to the cannabis industry. It is an honor to have been chosen by MJIC Media to sponsor their inaugural white paper."

CLS Holdings USA, Inc. (CLSH), closed Wednesday's trading session at $0.85, up 2.41%, on 42,545 volume with 6 trades. The average volume for the last 60 days is 6,510 and the stock's 52-week low/high is $0.72/$1.80.


The QualityStocks
Company Corner


Nutra Pharma Corp. (NPHC)

The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.11, off by 0.90%, on 733,786 volume with 67 trades. The stock’s average daily volume over the past 60 days is 145,679, and its 52-week low/high is $0.0025/$0.27.

Nutra Pharma Corp. announced today that they have applied for an Orphan Drug designation from the US-FDA for the Company's RPI-78M drug candidate for the treatment of Myasthenia Gravis (MG). On September 8, 2015, the Company announced that they had been granted an Orphan Designation for the treatment of Pediatric Multiple Sclerosis. The designation is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.

Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer

Nutra Pharma Corp. Company Blog

Nutra Pharma Corp. News:

Nutra Pharma Announces Additional Orphan Drug Application for RPI-78M for the Treatment of Myasthenia Gravis

StockNewsNow.com Publishes New SNNLive Video Interview With Nutra Pharma Corporation

Nutra Pharma's Rik Deitsch Interviewed by The Life Sciences Report

Hemp, Inc. (HEMP)

The QualityStocks Daily Newsletter would like to spotlight Hemp, Inc. (HEMP). Today, Hemp, Inc. closed trading at $0.056, off by 1.58%, on 1,857,838 volume with 125 trades. The stock’s average daily volume over the past 60 days is 3,536,129, and its 52-week low/high is $0.039/$1.00.

Hemp, Inc. was honored with the Jack Herer Cannabis Hemp Award in recognition of Hemp, Inc.'s "Major Achievement in the Hemp Industry". Producer and Co-Creator of the Jack Herer Cannabis Awards, Michael Whalen, recognized Perlowin and Hemp, Inc. as having a major impact within the industrial hemp industry with the only commercial industrial hemp decortication facility in the United States. Perlowin was also applauded on shifting the company's focus towards more advanced processing in the milling line.

Hemp, Inc. (HEMP) is engaged in the research and development of all things made of industrial hemp. From fabric, paper, cosmetics, food and jewelry to pulp, fuel, paints and more, the application of hemp represents a myriad of possibilities. The company strategizes to recognize the profits that could be made in making the world a better place through the industrial commercialization of this resource.

Hemp, Inc. subsidiaries include Industrial Hemp Manufacturing, LLC, which will soon be offering DrillWall™ for maintaining the seals on drilling for water, oil, gas and any other liquid or gas; and The Industrial Hemp and Medical Marijuana Consulting Company, Inc., which pulls pertinent market information from a vast network of professionals, specialists and experts from various niches of the hemp industry.

Las Vegas-based Hemp, Inc. conducts its operations through its 70,000-square-foot processing plant and decortication line of equipment, which is useful manufacturing more than 50,000 commercial products. The company's current line of offerings include hemp-infused body candles, shampoo and conditioner, smoothies, jewelry, healing oils, twine, lip balm and skin moisturizers.

Hemp products are used all over America every day and are sold in the largest and most respected stores. Not to be confused with marijuana, hemp does not contain psychoactive compounds and is legal in the United States and most of the world. Hemp, Inc.'s mission is to educate the public on this important differentiation while working to expand corporate infrastructure and invest in profitable, legal and diversified ventures poised to bring reward and value to shareholders. Disclaimer

Hemp, Inc. Company Blog

Hemp, Inc. News:

Hemp, Inc. CEO Receives the 1st Annual Jack Herer Cannabis Hemp Award

Two Days Left to Buy Hemp Jeans by Hemp Blue

National Hemp Association (NHA) Introduces Hemp, Inc. as Its Newest Gold Member

Freedom Leaf Inc. (FRLF)

The QualityStocks Daily Newsletter would like to spotlight Freedom Leaf Inc. (FRLF). Today, Freedom Leaf Inc. closed trading at $0.35, even for the day, on 10 volume with 1 trade. The stock’s average daily volume over the past 60 days is 387, and its 52-week low/high is $0.05/$1.00.

Freedom Leaf Inc. (FRLF), The Marijuana Legalization Company™, is a leading marijuana-related news, multi-media, entertainment, branding, business development, and incubation company with an ever-expanding online presence.

As a staunch national advocate of various state initiatives to legalize medical and recreational marijuana, Freedom Leaf has an entire platform of online content suited for every aspect of advertising and marketing for all businesses in the cannabis industry. These websites incorporate many aspects of the marijuana industry and movement. Freedom Leaf's current websites include:

•    FreedomLeaf.com

•    MarijuanaNews.com

•    LadyCannabis.com

•    Cannabis Business University

•    CannabisSeminars.com

•    CampusCannabisDebate.com

•    CannaSpa.com

•    Vegasterdam.com

Freedom Leaf founders have been involved in marijuana legalization for more than 45 years, delivering to the corporation keen industry insight and guidance on expansion initiatives. Freedom Leaf does not handle, grow, sell or dispense marijuana or related products, and therefore is not regulated in any way by the different government agencies other than standard business type of regulations. Disclaimer

Freedom Leaf Inc. Company Blog

Freedom Leaf Inc. News:

Freedom Leaf Licensing Its Brand for National Growth on the Grass Roots Level

Freedom Leaf, Inc. Named as Brand Ambassador of NORML

Freedom Leaf, Inc. (FRLF) Announces Engagement of QualityStocks Investor Relations Services

Avant Diagnostics, Inc. (AVDX)

The QualityStocks Daily Newsletter would like to spotlight Avant Diagnostics, Inc. (AVDX). Today, Avant Diagnostics, Inc. closed trading at $0.40, up 11.11%, on 5,296 volume with 10 trades. The stock’s average daily volume over the past 60 days is 1,867, and its 52-week low/high is $0.2002/$1.95.

Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.

OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.

As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market. Disclaimer

Avant Diagnostics, Inc. Company Blog

Avant Diagnostics, Inc. News:

Avant Diagnostics Inc. Receives FDA IRB Approval for OvaDx(R) Ovarian Cancer Validation Test Specimens

Avant Diagnostics Inc. Engages Goal Capital Inc. to Provide Investor Relations Services

Avant Diagnostics, Inc. Appoints Marcum LLP as Its New Independent Registered Public Accounting Firm

Elephant Talk Communications Corp. (ETAK)

The QualityStocks Daily Newsletter would like to spotlight Elephant Talk Communications Corp. (ETAK). Today, Elephant Talk Communications Corp. closed trading at $0.2473, up 7.52%, on 257,886 volume with 142 trades. The stock’s average daily volume over the past 60 days is 127,023, and its 52-week low/high is $0.205/$0.88.

Elephant Talk Communications Corp. (ETAK) provides mobile proprietary Software Defined Network Architecture (ET Software DNA® 2.0) platforms for its growing base of strategic partners and clients, which includes some of today's world-leading MNOs and technology companies, including Vodafone, T-Mobile, Zain, HP and Affirmed Networks.

Targeting its share of the broader $1.4+ trillion telecommunications market, Elephant Talk empowers MNOs, MVNOs, MVNEs and MVNAs with a full suite of applications, reliable industry expertise, and high quality customer service. Understanding that partnership is crucial in enabling and delivering the highest level of quality of product capability and professionalism, Elephant Talk also closely collaborates with other expert organizations and leading service providers.

ValidSoft UK Ltd., a subsidiary of Elephant Talk uses personal authentication and device assurance to secure transactions and help customers reduce fraud losses. As part of its multi-factor authentication, ValidSoft integrates its leading Voice Biometric engine into multivendor solutions or as a standalone system. ValidSoft serves multiple clients in the financial government and business automation sectors and is the only company to have been granted four European Privacy Seals, reflecting its commitment to promoting strong data privacy.

Elephant Talk has implemented rigid structures and processes to ensure corporate integrity and the responsible oversight of all business activities. This vision starts with executive management and extends to every employee. Elephant Talk is guided by a visionary leadership team with a rich history of success in key markets pertinent to both the company's current and desired market positions. In order to achieve and maintain world-class system performance, Elephant Talk leverages this management team along with collaborations with the world's best technical partners. Disclaimer

Elephant Talk Communications Corp. Company Blog

Elephant Talk Communications Corp. News:

Elephant Talk Communications Announces the Appointment of Robert H. Turner as Executive Chairman; Names ETNA President Tim Payne as Interim CEO

Elephant Talk Reports 2015 Third Quarter Financial Results and Conference Call

Elephant Talk to Reschedule 2015 Third Quarter Financial Results Conference Call


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





Wolf of Penny Stocks



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251